Keep these coming, more and more, although they are unfortunately slow to monetize.
The wait is long, especially since all parties must proceed slowly through pilots for each cancer type separately before this becomes mainstream.
*> Aiforia selected as AI partner for PROSTIA project – expanding to five new hospitals in Paris
Aiforia France, a subsidiary of Aiforia Technologies Plc, has been selected as the AI partner for the PROSTIA project led by Assistance Publique–Hôpitaux de Paris (AP-HP). In this project, Aiforia’s CE-IVD marked prostate cancer diagnostic solution will be implemented across all AP-HP pathology sites involved in the treatment of prostate diseases, expanding the collaboration started in 2024 at AP-HP’s Bicêtre and Saint-Louis hospitals to five new hospitals.
Through the project, all 3,000 prostate biopsy cases examined annually at AP-HP will be analyzed using Aiforia’s AI technology. This is one of Europe’s first large-scale implementations of AI in routine pathology.
The new agreements are part of the two-year PROSTIA project funded by Bpifrance, which is a significant, large-scale strategic initiative supported by the national France 2030 program. The project aims to evaluate the impact of AI-assisted tools on prostate cancer diagnostics.
PROSTIA is a flagship project that illustrates the large-scale implementation of AI in clinical diagnostics and its concrete, measurable effects on organizations and pathology workflows. The goal is to evaluate the medical, operational, and economic impacts of AI integration on routine pathology diagnostics, specifically for prostate cancer samples. This medical and economic evaluation will provide the baseline data to consider including AI solutions in the pathology reimbursement system. In the long term, the project aims to expand the use of AI to other use cases.
”Our participation in the PROSTIA project is a significant milestone in bringing AI-assisted diagnostics into routine clinical use in France. The project lays the groundwork for the broader adoption of AI across various pathology use cases. France is an important market for us, and it is great to be able to support hospitals in integrating AI into pathology workflows,” says Aiforia CEO Jukka Tapaninen.
Aiforia selected as AI partner for PROSTIA project - expanding to five new hospitals in Paris Aiforia on valittu tekoälykumppaniksi PROSTIA-hankkeeseen - laajentaa viiteen uuteen sairaalaan Pariisissa